Development and Validation of the Indian Asthma Care Bundle for Reducing Readmission and Improving Post-hospitalisation Care After Discharge From Hospital Due to an Acute Asthma Exacerbation

Condition(s) studied

Investigational drug(s) / intervention(s)

Indian Asthma Care Bundle (I-ACB): I-ACB is a structured hospital-initiated asthma care bundle (I-ACB), a contextual and India-specific post-discharge care bundle tailored for adult asthma patients hospitalised for asthma.

Study summary

The goal of this study is to assess the effectiveness of the Indian Asthma Care Bundle (I-ACB) in improving post-discharge asthma management among patients with asthma in India, specifically targeting adults and children experiencing severe asthma exacerbations.

The main questions it aims to answer are:

1. Does the I-ACB reduce the rate of hospital readmissions within 30, 60, and 90 days post-discharge?
2. How does the I-ACB impact treatment adherence, lung function, symptom control, and overall quality of life, compared to usual care?

Researchers will compare outcomes among participants receiving the I-ACB with those receiving standard asthma care (usual care) to determine whether the I-ACB improves health outcomes and reduces the need for emergency department visits.

Participants will be asked to:

* Engage in a structured asthma management program that includes education on inhaler techniques and adherence to treatment plans.
* Report their symptoms and treatment adherence regularly.
* Participate in follow-up assessments that monitor lung function and quality of life over a specified period.

The importance of this study lies in its potential to address significant gaps in asthma management in India, which currently lead to high hospitalisation rates and substantial healthcare costs. By developing a tailored care strategy, the I-ACB aims to improve health outcomes for millions of asthma patients, reducing the burden on families and healthcare systems alike, and ultimately transforming the approach to asthma care in the region.

Eligibility

Primary outcome measure(s)

• Hospital readmission or emergency department visit — 30, 60, and 90 days post-discharge
  Any readmission or emergency department within the first 30, 60, and 90 days after discharge from exacerbation-related hospitalisation will be assessed by telephonic interviews or by accessing hospital logs.

Trial sites (2)